These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20161568)

  • 1. PREVENTION OF ATHEROSCLEROSIS WITH LDL-C LOWERING - LIPOPROTEIN CHANGES AND INTERACTIONS: THE SANDS STUDY.
    Howard WJ; Russell M; Fleg JL; Mete M; Ali T; Devereux RB; Galloway JM; Otvos JD; Ratner RE; Roman MJ; Silverman A; Umans JG; Weissman NJ; Wilson C; Howard BV
    J Clin Lipidol; 2009 Oct; 3(5):322-331. PubMed ID: 20161568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.
    Fleg JL; Mete M; Howard BV; Umans JG; Roman MJ; Ratner RE; Silverman A; Galloway JM; Henderson JA; Weir MR; Wilson C; Stylianou M; Howard WJ
    J Am Coll Cardiol; 2008 Dec; 52(25):2198-205. PubMed ID: 19095139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience.
    Mete M; Wilson C; Lee ET; Silverman A; Russell M; Stylianou M; Umans JG; Wang W; Howard WJ; Ratner RE; Howard BV; Fleg JL
    J Diabetes Complications; 2011; 25(6):362-7. PubMed ID: 21775166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordance of Apolipoprotein B, Non-HDL-Cholesterol, and LDL-Cholesterol Predicts Risk of Increased Arterial Stiffness and Elevated Carotid Intima-Media Thickness in Middle-Aged and Elderly Chinese Adults.
    Jia X; Qi Y; Zheng R; Lin L; Hu C; Zhu Y; Cao Q; Wu X; Qi H; Wei R; Zhang Y; Xu M; Xu Y; Wang T; Zhao Z; Chen Y; Li M; Wang W; Bi Y; Lu J
    Front Cardiovasc Med; 2022; 9():906396. PubMed ID: 35665267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women.
    Maki KC; Dicklin MR; Davidson MH; Mize PD; Kulkarni KR
    Vasc Health Risk Manag; 2012; 8():31-8. PubMed ID: 22272073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
    Ballantyne CM; Raichlen JS; Cain VA
    J Am Coll Cardiol; 2008 Aug; 52(8):626-32. PubMed ID: 18702965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LDL-cholesterol to HDL-cholesterol ratio discordance with lipid parameters and carotid intima-media thickness: a cohort study in China.
    Lou Y; Li X; Cao L; Qin P; Shi J; Zhang Y; Wang C; Ma J; Wang L; Peng X; Chen H; Xu S; Hu F; Zhao Y; Zhao P
    Lipids Health Dis; 2020 Jun; 19(1):141. PubMed ID: 32552893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines.
    Sathiyakumar V; Park J; Quispe R; Elshazly MB; Michos ED; Banach M; Toth PP; Whelton SP; Blumenthal RS; Jones SR; Martin SS
    Circulation; 2018 Jul; 138(3):244-254. PubMed ID: 29506984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Low-Density Lipoprotein Cholesterol/High-Density Lipoprotein Cholesterol Concentration Ratio and Early Marker of Carotid Artery Atherosclerosis.
    Nimkuntod P; Tongdee P
    J Med Assoc Thai; 2015 May; 98 Suppl 4():S58-63. PubMed ID: 26201135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study).
    Ikeda K; Takahashi T; Yamada H; Matsui K; Sawada T; Nakamura T; Matsubara H;
    Eur J Prev Cardiol; 2013 Dec; 20(6):1069-79. PubMed ID: 22689416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.
    Marston NA; Giugliano RP; Melloni GEM; Park JG; Morrill V; Blazing MA; Ference B; Stein E; Stroes ES; Braunwald E; Ellinor PT; Lubitz SA; Ruff CT; Sabatine MS
    JAMA Cardiol; 2022 Mar; 7(3):250-256. PubMed ID: 34773460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).
    Mackey RH; Greenland P; Goff DC; Lloyd-Jones D; Sibley CT; Mora S
    J Am Coll Cardiol; 2012 Aug; 60(6):508-16. PubMed ID: 22796256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials.
    Robinson JG; Wang S; Jacobson TA
    Am J Cardiol; 2012 Nov; 110(10):1468-76. PubMed ID: 22906895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.
    Kones R
    Drug Des Devel Ther; 2011; 5():325-80. PubMed ID: 21792295
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.